Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Classification of general epidemiological and clinical uses and common terminology criteria for adverse events

Common terminology criteria for adverse events

The National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) developed the original Common Toxicity Criteria (CTC) in 1982 in an effort to provide a standard language for reporting adverse events occurring in cancer clinical trials sponsored by the NCI. CTC is widely accepted throughout the oncology research community as the standard grading scale for adverse events. The CTC has substantially evolved since its inception in 1982. The most recent version is the Common Terminology Criteria for Adverse Events (CTCAE). 1 The terminology provided for the grading of skin toxicity on this website includes the latest CTCAE version, Version 5.0. Despite its widespread use and its utility, the CTCAE has not been validated.

MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT)

The MESTT2 was developed in 2008 by the MASCC Skin Toxicity Study Group as a tool to assist oncology health professions with the monitoring and reporting of dermatologic AEs in EGFRI-treated patients. The MESTT is an event-specific grading system that can be used to standardise assessment, optimise the use of EGFR inhibitors and enable researchers to conduct more informative, controlled studies in this patient population.Related Links


  1. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events and Common Toxicity Criteria [v5.0]. 27 November 2017. (Accessed 15 April 2019).
  2. Wollenberg A, et al. Exp Dermatol. 2008; 17: 790-792.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings